Whittier Trust Co. Boosts Stock Position in Stryker Corporation $SYK

Whittier Trust Co. boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 9.3% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,466 shares of the medical technology company’s stock after acquiring an additional 380 shares during the quarter. Whittier Trust Co.’s holdings in Stryker were worth $1,767,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Stryker in the 2nd quarter worth $26,000. Sachetta LLC lifted its holdings in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after buying an additional 27 shares during the period. Goodman Advisory Group LLC purchased a new stake in shares of Stryker in the 1st quarter worth $32,000. Ridgewood Investments LLC lifted its holdings in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares during the period. Finally, Ransom Advisory Ltd purchased a new stake in shares of Stryker in the 1st quarter worth $37,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 2.1%

Stryker stock opened at $387.84 on Thursday. The stock has a 50-day moving average of $379.74 and a two-hundred day moving average of $379.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The stock has a market cap of $148.27 billion, a PE ratio of 51.37, a price-to-earnings-growth ratio of 2.74 and a beta of 0.94.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the business posted $2.81 earnings per share. The firm’s revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Rothschild & Co Redburn assumed coverage on Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. Rothschild Redb raised Stryker to a “hold” rating in a research report on Thursday, September 18th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, BTIG Research boosted their price target on Stryker from $407.00 to $408.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $432.24.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.